S&P 500   4,594.58 (-1.30%)
DOW   34,684.68 (-1.28%)
QQQ   397.38 (-0.58%)
AAPL   163.78 (+2.21%)
MSFT   334.48 (-0.64%)
FB   331.41 (-1.96%)
GOOGL   2,885.15 (-0.87%)
AMZN   3,541.44 (-0.57%)
TSLA   1,153.49 (+1.45%)
NVDA   326.78 (-2.09%)
BABA   128.07 (-2.69%)
NIO   39.88 (-1.43%)
CGC   10.68 (-3.44%)
AMD   160.87 (-0.64%)
GE   96.40 (-2.03%)
MU   85.66 (-0.56%)
T   22.94 (-3.98%)
F   19.57 (-0.51%)
DIS   145.81 (-1.35%)
ACB   6.36 (-1.24%)
AMC   35.05 (-4.86%)
PFE   53.71 (+2.50%)
BA   196.70 (-0.91%)
S&P 500   4,594.58 (-1.30%)
DOW   34,684.68 (-1.28%)
QQQ   397.38 (-0.58%)
AAPL   163.78 (+2.21%)
MSFT   334.48 (-0.64%)
FB   331.41 (-1.96%)
GOOGL   2,885.15 (-0.87%)
AMZN   3,541.44 (-0.57%)
TSLA   1,153.49 (+1.45%)
NVDA   326.78 (-2.09%)
BABA   128.07 (-2.69%)
NIO   39.88 (-1.43%)
CGC   10.68 (-3.44%)
AMD   160.87 (-0.64%)
GE   96.40 (-2.03%)
MU   85.66 (-0.56%)
T   22.94 (-3.98%)
F   19.57 (-0.51%)
DIS   145.81 (-1.35%)
ACB   6.36 (-1.24%)
AMC   35.05 (-4.86%)
PFE   53.71 (+2.50%)
BA   196.70 (-0.91%)
S&P 500   4,594.58 (-1.30%)
DOW   34,684.68 (-1.28%)
QQQ   397.38 (-0.58%)
AAPL   163.78 (+2.21%)
MSFT   334.48 (-0.64%)
FB   331.41 (-1.96%)
GOOGL   2,885.15 (-0.87%)
AMZN   3,541.44 (-0.57%)
TSLA   1,153.49 (+1.45%)
NVDA   326.78 (-2.09%)
BABA   128.07 (-2.69%)
NIO   39.88 (-1.43%)
CGC   10.68 (-3.44%)
AMD   160.87 (-0.64%)
GE   96.40 (-2.03%)
MU   85.66 (-0.56%)
T   22.94 (-3.98%)
F   19.57 (-0.51%)
DIS   145.81 (-1.35%)
ACB   6.36 (-1.24%)
AMC   35.05 (-4.86%)
PFE   53.71 (+2.50%)
BA   196.70 (-0.91%)
S&P 500   4,594.58 (-1.30%)
DOW   34,684.68 (-1.28%)
QQQ   397.38 (-0.58%)
AAPL   163.78 (+2.21%)
MSFT   334.48 (-0.64%)
FB   331.41 (-1.96%)
GOOGL   2,885.15 (-0.87%)
AMZN   3,541.44 (-0.57%)
TSLA   1,153.49 (+1.45%)
NVDA   326.78 (-2.09%)
BABA   128.07 (-2.69%)
NIO   39.88 (-1.43%)
CGC   10.68 (-3.44%)
AMD   160.87 (-0.64%)
GE   96.40 (-2.03%)
MU   85.66 (-0.56%)
T   22.94 (-3.98%)
F   19.57 (-0.51%)
DIS   145.81 (-1.35%)
ACB   6.36 (-1.24%)
AMC   35.05 (-4.86%)
PFE   53.71 (+2.50%)
BA   196.70 (-0.91%)
NASDAQ:THRX

Theseus Pharmaceuticals Stock Forecast, Price & News

$14.04
-0.45 (-3.11%)
(As of 11/30/2021 10:51 AM ET)
Add
Today's Range
$14.04
$14.71
50-Day Range
N/A
52-Week Range
$13.71
$24.54
Volume
389 shs
Average Volume
243,842 shs
Market Capitalization
$543.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive THRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Theseus Pharmaceuticals logo

About Theseus Pharmaceuticals

Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

Headlines

33 Stocks Moving In Monday's Mid-Day Session
November 29, 2021 |  msn.com
Theseus Pharmaceuticals (NASDAQ:THRX) Shares Down 14.6%
November 29, 2021 |  americanbankingnews.com
Theseus Pharmaceuticals (NASDAQ:THRX) Shares Gap Down to $17.65
November 24, 2021 |  americanbankingnews.com
Theseus Pharmaceuticals (NASDAQ:THRX) Sees Large Volume Increase
November 23, 2021 |  americanbankingnews.com
Theseus Pharmaceuticals (NASDAQ:THRX) Stock Price Down 8.1%
November 22, 2021 |  americanbankingnews.com
Theseus Pharmaceuticals (NASDAQ:THRX) Shares Up 7.1%
November 19, 2021 |  americanbankingnews.com
Theseus Pharmaceuticals (NASDAQ:THRX) Issues Earnings Results
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:THRX
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,156,000
Market Cap
$543.39 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/21/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Theseus Pharmaceuticals (NASDAQ:THRX) Frequently Asked Questions

Is Theseus Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Theseus Pharmaceuticals stock.
View analyst ratings for Theseus Pharmaceuticals
or view top-rated stocks.

When is Theseus Pharmaceuticals' next earnings date?

Theseus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Theseus Pharmaceuticals
.

How were Theseus Pharmaceuticals' earnings last quarter?

Theseus Pharmaceuticals Inc (NASDAQ:THRX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($5.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $4.93.
View Theseus Pharmaceuticals' earnings history
.

What price target have analysts set for THRX?

4 brokers have issued 12-month price objectives for Theseus Pharmaceuticals' stock. Their forecasts range from $23.00 to $28.00. On average, they anticipate Theseus Pharmaceuticals' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 75.6% from the stock's current price.
View analysts' price targets for Theseus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

When did Theseus Pharmaceuticals IPO?

(THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at a price of $14.00-$16.00 per share.

What is Theseus Pharmaceuticals' stock symbol?

Theseus Pharmaceuticals trades on the NASDAQ under the ticker symbol "THRX."

When did Theseus Pharmaceuticals' quiet period expire?

Theseus Pharmaceuticals' quiet period expired on Tuesday, November 16th. Theseus Pharmaceuticals had issued 10,000,200 shares in its IPO on October 7th. The total size of the offering was $160,003,200 based on an initial share price of $16.00. During Theseus Pharmaceuticals' quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Theseus Pharmaceuticals?

Shares of THRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theseus Pharmaceuticals' stock price today?

One share of THRX stock can currently be purchased for approximately $14.24.

How much money does Theseus Pharmaceuticals make?

Theseus Pharmaceuticals has a market capitalization of $551.13 million.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.